Pharmacogenetics of dopamine receptors and response to antipsychotic drugs in schizophrenia - An update

Pharmacogenomics

Volumn 5, Issue 6, 2004, Pages 691-698

  Scharfetter, Joachim ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Antipsychotic; Association; Dopamine; Pharmacogenetic; Polymorphism; Receptor; Response

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; BROMPERIDOL; CLOZAPINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE 4 RECEPTOR; DOPAMINE 5 RECEPTOR; DOPAMINE RECEPTOR; EMONAPRIDE; GLYCINE; NEUROLEPTIC AGENT; RISPERIDONE; SERINE;

DRUG RECEPTOR BINDING; DRUG RESPONSE; GENE LINKAGE DISEQUILIBRIUM; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; PHARMACOGENETICS; PROTEIN FUNCTION; RATING SCALE; REVIEW; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM;

ANTIPSYCHOTIC AGENTS; CLINICAL TRIALS; HUMANS; PHARMACOGENETICS; RECEPTORS, DOPAMINE; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; RECEPTORS, DOPAMINE D4; SCHIZOPHRENIA;

EID: 4544344215     PISSN: 14622416     EISSN: None     Source Type: Journal    
DOI: 10.1517/14622416.5.6.691     Document Type: Review

References (58)

1. Scharfetter J: Dopamine receptor polymorphism and drug response in schizophrenia. Pharmacogenomics 2, 251-261 (2001).
2. Shaikh S, Collier D, Arranz M, Ball D, Gill M, Kerwin R: DRD2 Ser311/Cys311 polymorphism in schizophrenia. Lancet 343, 1045-1046 (1994).
3. Arranz MJ, Li T, Munro J et al.: Lack of association between a polymorphism in the promoter region of the dopamine-2 receptor gene and clozapine response. Pharmacogenetics 8, 481-484 (1998).
4. Suzuki A, Mihara K, Kondo T et al.: The relationship between dopamine D2 receptor polymorphism at the Taq1 A locus and therapeutic response to nemonapride, a selective dopamine antagonist, in schizophrenic patients. Pharmacogenetics 10(4), 335-341 (2000).
5. Ohara K, Nakamura Y, Xie DW et al.: Polymorphisms of dopamine D2-like (D2, D3, and D4) receptors in schizophrenia. Biol. Psychiatry 40, 1209-1217 (1996).
6. Schäfer M, Rujescu D, Giegling I et al.: Association of short-term response to haloperidol treatment with a polymorphism in the dopamine D2 receptor gene. Am. J. Psychiatry 158, 802-804 (2001).
7. Nimgaonkar VL, Zhang XR, Caldwell JG, Ranguli R, Chakravarti A: Association study of schizophrenia with dopamine D3 receptor gene polymorphisms: probable effects of family history of schizophrenia? Am. J. Med. Genet. (Neuropsychiat. Genet.) 48, 214-217 (1993).
8. Jönnson E, Lannfelt L, Sokoloff P, Schwartz JC, Sedvall G: Lack of association between schizophrenia and alleles in the dopamine D3 receptor gene. Acta Psychiatr. Scand. 87, 345-349 (1993).
9. Yang L, Li T, Wiese C et al.: No association between schizophrenia and homozygosity at the D3 dopamine receptor gene. Am. J. Med. Genet. 48, 83-86 (1993).
10. Mant R, Williams J, Asherson P, Parfitt E, McGuffin P, Owen MJ: Relationship between homozygosity at the dopamine D3 receptor gene and schizophrenia. Am. Med. Genet. 54, 21-26 (1994).
11. Kennedy JL, Billett EA, Maccardi FM et al.: Association study of dopamine D3 receptor gene and schizophrenia. Am. J. Med. Genet. 60, 558-562 (1995).
12. Shaikh S, Collier DA, Sham PC et al.: Allelic association between a Ser-9-Gly polymorphism in the dopamine D3 receptor gene and schizophrenia. Hum. Genet. 97, 714-719 (1996).
13. Nimgaonkar VL, Sanders AR, Ganguli R et al.: Association study of schizophrenia and the dopamine D3 receptor gene locus in two independent samples. Am. J. Med. Genet. 67, 505-514 (1996).
14. Gaitonde EJ, Morris A, Sivagnanasundaram S, McKenna PJ, Hunt DM, Mollon JD: Assessment of association of D3 dopamine receptor MscI polymorphism with schizophrenia: analysis of symptoms ratings, family history, age at onset, and movement disorders. Am. J. Med. Genet. 67, 455-458 (1996).
15. Durany N, Thome J, Palomo A, Foley P, Riederer P, Cruz-Sanchez FF: Homozygosity at the dopamine D3 receptor gene in schizophrenic patients. Neurosci. Lett. 220, 151-154 (1996).
16. Ebstein RP, Macciardi F, Heresco-Levi U et al.: Evidence of an association between the dopamine D3 receptor gene DRD3 and schizophrenia. Hum. Hered. 47, 6-16 (1997).
17. Malhotra AK, Goldman D, Buchanan RW et al.: The dopamine D3 receptor (DRD3) Ser9Gly polymorphism and schizophrenia: a haplotype relative risk study and association with clozapine response. Mol. Psychiatr. 3, 72-75 (1998).
18. Krebs MO, Sautel F, Bourdel MC et al.: Dopamine D3 receptor gene variants and substance abuse in schizophrenia. Mol. Psychiatr. 3, 337-341 (1998).
19. Scharfetter J, Chaudhry HR, Hornik K et al.: Dopamine D3 receptor gene polymorphism and response to clozapine in schizophrenic pakistani patients. Eur. Neuropsychopharmacol. 10, 17-20 (1999).
20. Joober R, Toulouse A, Benkelfat C et al.: DRD3 and DAT1 genes in schizophrenia: an association study. J. Psychiatr. Res. 34, 285-291 (2000).
21. Shaikh S, Collier D, Kerwin RW et al.: Dopamine D4 receptor subtypes and response to clozapine. Lancet 341, 116 (1993).
22. Kerwin RW, Pilowsky L, Munro J, Shaikh S, Gill M, Collier D: Functional neuroimaging and pharmacogenetic studies of clozapine's action at dopamine receptors. J. Clin. Psychiatry 55(Suppl. B), 57-62 (1994).
23. Rao PA, Pickar D, Gejman PV, Ram A, Gershon ES, Gelernter J: Allelic variation in the D4 dopamine receptor (DRD4) gene does not predict response to clozapine. Arch. Gen. Psychiatry 51, 912-917 (1994).
24. Shaikh S, Collier DA, Sham P et al.: Analysis of clozapine response and polymorphisms of the dopamine D4 receptor gene (DRD4) in schizophrenic patients. Am. J. Med. Genet. (Neuropsychiat. Genet.) 60, 541-545 (1995).
25. Rietschel M, Naber D, Oberländer H et al.: Efficacy and side effects of clozapine: testing for association with allelic variation in the dopamine D4 receptor gene. Neuropsychopharmacology 15(5), 491-496 (1996).
26. Kohn Y, Ebstein RP, Heresco-Levy U et al.: Dopamine D4 receptor gene polymorphisms: relation to ethnicity, no association with schizophrenia and response to clozapine in israeli subjects. Eur. Neuropsychopharmacol. 7, 39-43 (1997).
27. Hwu HG, Hong CJ, Lee YL, Lee PC, Lee SFC: Dopamine D4 receptor gene polymorphisms and neuroleptic response in schizophrenia. Biol. Psychiatry 44, 483-487 (1998).
28. Cohen BM, Ennulat DJ, Centorrino F et al.: Polymorphisms of the dopamine D4 receptor and response to antipsychotic drugs. Psychopharmacology 141, 6-10 (1999).
29. Kaiser R, Könnecker M, Henneken M et al.: Dopamine receptor 48-bp repeat polymorphism: no association with response to antipsychotic treatment, but association with catatonic schizophrenia. Mol. Psychiatr. 5, 418-424 (2000).
30. Ohara K, Nagai M, Tani K, Nakamura Y, Ino A, Ohara K: Functional polymorphism of -141C Ins/Del in the dopamine D2 receptor gene promoter and schizophrenia. Psychiatry Res. 81, 117-123 (1998).
31. Malhotra AK, Buchanan RW, Kim S et al.: Allelic variation in the promoter region of the dopamine D2 receptor gene and clozapine response. Schizophr. Res. 36, 92-93 (1999).
32. Suzuki A, Kondo T, Mihara K et al.: The -141C Ins/Del polymorphism in the dopamine D2 receptor gene promoter region is associated with anxiolytic and antidepressive sffects during treatment with dopamine antagonists in schizophrenic patients. Pharmacogenetics 11, 545-550 (2001).
33. Suzuki A, Kondo T, Mihara K et al.: Association between Taq1 A dopamine D2 receptor polymorphism and therapeutic response to bromperidol: a preliminary report. Eur. Arch. Psychiatry Clin. Neurosci. 251, 57-59 (2001).
34. Dahmen N, Müller MJ, Germeyer S et al.: Genetic polymorphisms of the dopamine D2 and D3 receptor and neuroleptic drug effects in schizophrenic. Schizophr. Res. 49, 223-225 (2001).
35. Yamanouchi Y, Iwata N, Suzuki T, Kitajima T, Ikeda M, Ozaki N: Effect of DRD2, 5-HT2A, and COMT genes on antipsychotic response to risperidone. Pharmacogenomics J. 3, 356-361 (2003).
36. Kondo T, Mihara K, Suzuki A, Yasui-Furukori N, Kaneko S: Combination of dopamine D2 receptor gene polymorphism as a possible predictor of treatment-resistance to dopamine antagonists in schizophrenic patients. Prog. Neuropsychopharmacol. Biol. Psychiatry 27, 921-926 (2003).
37. Sivagnanasundaram S, Morris AG, Gaitonde EJ, McKenna P, Mollon JD, Hunt DM: A cluster of single nucleotide polymorphisms in the 5′-leader of the human dopamine D3 receptor gene (DRD3) and its relationship to schizophrenia. Neurosci. Lett. 279, 13-16 (2000).
38. Szekeres G, Keri S, Juhasz A et al.: Role of dopamine D3 receptor (DRD3) and dopamine transporter (DAT) polymorphism in cognitive dysfunctions and therapeutic response to atypical antipsychotics in patients with schizophrenia. Am. J. Med. Genet. 124B, 1-5 (2004).
39. Jönsson EG, Flyckt L, Burgert E et al.: Dopamine D3 receptor gene Ser9Gly variant and schizophrenia: association study and meta-analysis. Psychiatr. Genet. 13, 1-12 (2003).
40. Zalsman G, Frisch A, Lev-Ran S et al.: DRD4 exon III polymorphism and response to risperidone in Israeli adolescents with schizophrenia: a pilot pharmacogenetic study. Eur. Neurophsychopharmacol. 13, 183-185 (2003).
41. Basile VS, Masellis M, McIntyre RS, Meltzer HY, Lieberman JA, Kennedy JL: Genetic dissection of atypical antipsychotic-induced wheight gain: novel preliminary data on the pharmacogenetic puzzle. J. Clin. Psychiatr. 62(Suppl. 23), 45-66 (2001).
42. Ohmori O, Shinkai T, Hori H, Matsumoto C, Nakamura J: A perspective on molecular genetic studies of tardive dyskinesia: one clue for individualized antipsychotic drug therapy. Prog. Neuropsychopharmacol. Biol. Psychiatr. 27, 581-586 (2003).
43. Potkin SG, Basile VS, Jin Y et al.: D1 receptor alleles predict PET metabolic correlates of clinical response to clozapine. Mol. Psychiatry 8, 109-113 (2003).
44. Basile VS, Masellis M, Potkin SG, Kennedy JL: Pharmacogenomics in schizophrenia: the quest for individualized therapy. Hum. Mol. Genet. 11, 2517-2530 (2002).
45. Arinami T, Gao M, Hamaguchi H, Toru M: A functional polymorphism in the promoter region of the dopamine D2 receptor gene is associated with schizophrenia. Hum. Mol. Genet. 6, 577-582 (1997).
46. Jönsson EG, Nöthen MM, Grünhage F et al.: Polymorphisms in the dopamine D2 receptor gene and their relationship to striatal dopamine receptor density in healthy volunteers. Mol. Psychiatry 4, 290-296 (1999).
47. Pohjalainen T, Nagren K, Syvalahti EK, Hietala J: The dopamine D2 receptor 5′-flanking variant, -141C Ins/Del, is not associated with reduced dopamine D2 receptor density in vivo. Pharmacogenetics 9, 505-509 (1999).
48. Thompson J, Thomas N, Singleton A et al.: D2 dopamine receptor gene (DRD2) Taq1 A polymorphism: reduced dopamine D2 receptor binding in the human striatum associated with the A1 allele. Pharmacogenetics 7, 479-484 (1997).
49. Pohjalainen T, Rinne JO, Nagren K et al.: The A1 allele of the human D2 dopamine receptor gene predicts low D2 receptor availability in healthy volunteers. Mol. Psychiatry 3, 356-360 (1998).
50. Laruelle M, Gelernter J, Innis RB: D2 receptors binding potential is not affected by Taq1 polymorphism at the D2 receptor gene. Mol Psychiatry 3, 261-265 (1998).
51. Duan J, Wainwright MS, Comeron JM et al.: Synonymous mutations in the human dopamine receptor D2 (DRD2) affect mRNA stability and synthesis of the receptor. Hum. Mol. Genet. 12, 205-216 (2003).
52. Scarselli M, Novi F, Schallmach E et al.: D2/D3 dopamine receptor heterodimers; exhibit unique functional properties. J. Biol. Chem. 32, 30308-30314 (2001).
53. Asghari V, Sanyal S, Buchwaldt S et al.: Modulation of intracellular cyclic AMP levels by different human dopamine D4 receptor variants. J. Neurochem. 65, 1157-1165 (1995).
54. Kawanishi Y, Tachikawa H, Suzuki T Pharmacogenomics and schizophrenia. Eur. J. Pharmacol. 410, 227-241 (2000).
55. Lerer B, Segman RH, Fangerau H et al.: Pharmacogenetics of tardive dyskinesia: combined analysis of 780 patients supports assoziation with dopamine D3 receptor gene Ser9Gly polymorphism. Neuropsychopharmacology 27, 105-119 (2002).
56. Malhotra AK, Kennedy JL, Collier DA, Rietschel M: Pharmacogenetics in psychiatry, satellite meeting at the American College of Neuropsychopharmacology, 2000. Neuropsychopharmacology 26, 123-127 (2002).
57. Rosenberg NA, Pritchard JK, Weber JL et al.: Genetic structure of human populations. Science 298, 2381-2385 (2002).
58. Ozdemir V, Masellis M, Basile VS et al.: Variability in response to clozapine: potential role of cytochrome P450 1A2 and the dopamine D4 receptor gene. CNS Spectr. 4(6), 30-56 (1999).